Clinical trial
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients…
NCT00137423 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00137423 |
|---|---|
| Title | Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer |
| Official title | A Phase 2 Efficacy And Safety Study Of SU011248 Administered In A Continuous Daily Regimen In Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell Metastasis |
| Intervention type | Drug |
| Interventions | SU011248 (sunitinib) |
| Enrollment | 107 |
| Start date | May 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | May 1, 2008 |
| First posted | Aug 29, 2005 |
| Last update posted | Sep 30, 2009 |
| Countries | France, Germany, Greece, Netherlands, Sweden, Switzerland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: